Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Actinium Pharmaceuticals : Awarded Patents in Europe, Japan for Antibody Radiation Conjugate

06/17/2021 | 10:52am EDT


© MT Newswires 2021
All news about ACTINIUM PHARMACEUTICALS, INC.
10/04ACTINIUM PHARMACEUTICALS : Announces Two Abstracts Highlighting Combinations of CD47 Targe..
AQ
09/29ACTINIUM PHARMACEUTICALS : to Present at the Cantor Fitzgerald Virtual Global Healthcare C..
AQ
09/29ACTINIUM PHARMACEUTICALS RALLY TAKES : Atnm)
AQ
09/28ACTINIUM PHARMACEUTICALS : Announces Expansion of R&D Team and Facilities to Accelerate Re..
AQ
09/28GENPREX : Appoints Mark Berger Chief Medical Officer
MT
09/23ACTINIUM PHARMACEUTICALS : Announces Multiple Senior Leadership Appointments Including Chi..
PU
09/23ACTINIUM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regulation FD ..
AQ
09/23Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and..
CI
09/23ACTINIUM PHARMACEUTICALS RALLY INTAC : Atnm)
AQ
09/21ACTINIUM PHARMACEUTICALS STOCK JUMPS : Atnm)
AQ
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,02 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,22x
Yield 2021 -
Capitalization 166 M 166 M -
Capi. / Sales 2021 164x
Capi. / Sales 2022 10,8x
Nbr of Employees 32
Free-Float 98,5%
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,80 $
Average target price 30,00 $
Spread / Average Target 285%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Dale L. Ludwig Chief Scientific & Technology Officer
Avinash Desai Chief Medical Officer
Mary Mei Chen Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.3.08%166
GILEAD SCIENCES, INC.13.11%84 795
BIONTECH SE220.28%59 820
WUXI APPTEC CO., LTD.28.00%57 897
REGENERON PHARMACEUTICALS12.50%57 519
VERTEX PHARMACEUTICALS-23.50%47 156